Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 17/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 15/20 | 0.43 |
| ▸ | STS | P08842 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28165933 | 0.85 | XDH (0.38) | CYP11B2CYP11B1GRIA2 | |
| SCHEMBL3477333 | 0.82 | CYP11B2 (0.47) | CYP11B2CYP11B1CASP1 | |
| SCHEMBL751926 | 0.79 | CYP11B2 (0.43) | CYP11B2CYP11B1GRIA2 | |
| SCHEMBL3748498 | 0.79 | CYP11B2 (0.51) | CYP11B2CYP11B1 | |
| SCHEMBL3751450 | 0.77 | CYP11B2 (0.43) | CYP11B2CYP11B1CASP1 | |
| SCHEMBL6119593 | 0.77 | PIP4K2A (0.45) | CYP11B2CYP11B1 | |
| SCHEMBL751429 | 0.77 | CYP11B2 (0.47) | CYP11B2CYP11B1GRIA2 | |
| SCHEMBL745296 | 0.77 | CYP11B2 (0.47) | CYP11B2CYP11B1GRIA2 | |
| SCHEMBL29885851 | 0.77 | CYP11B2 (0.47) | CYP11B2CYP11B1GRIA2 | |
| SCHEMBL745295 | 0.77 | CYP11B2 (0.47) | CYP11B2CYP11B1GRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2429995-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | Novartis AG (CH) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010130796-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2010-11-18 | — | — | WO | disclosed |